Abivax Secures Spot in CAC Mid 60 and SBF 120 Indices

Author: Logan Wright Updated: 09-12-2025 11:58 AM

Abivax Gains Recognition in Euronext Paris Indices

Today marks a significant milestone for Abivax SA, a pioneering biotechnology company dedicated to developing therapies that utilize the body’s innate regulatory mechanisms to support patients with chronic inflammatory diseases. The company is thrilled to announce its upcoming inclusion in both the CAC Mid 60 and SBF 120 indices following a review conducted by Euronext Paris.

Importance of Index Inclusion

This announcement is based on the findings from the annual review which took place recently, with the new adjustments taking effect after market close on an upcoming Friday. Being part of the CAC Mid 60 and SBF 120 not only reinforces Abivax's stature within the European trading landscape, but it also serves to enhance the visibility of its shares in the market.

Strategic Benefits for Abivax

Inclusion in these indices is expected to expand Abivax’s investor base considerably. By becoming more accessible to institutional investors and those interested in index-linked funds, Abivax is poised to attract attention from a broader range of market participants.

Words from Leadership

Marc de Garidel, the CEO of Abivax, expressed his excitement over this achievement. He stated, "We feel honored to join the ranks of notable companies in the CAC Mid 60 and SBF 120 indices. This acknowledgment reflects the financial community's trust in our strategic plans and our capacity to bring them to fruition. Furthermore, it reaffirms our commitment to developing innovative therapies for patients battling chronic inflammatory diseases and enhancing shareholder value.”

About Abivax and Its Pipeline

Abivax operates with a vision to revolutionize the treatment for chronic inflammatory diseases by leveraging the body's own regulatory systems. With both headquarters in France and the United States, the firm is currently advancing its lead candidate, obefazimod (ABX464), through Phase 3 clinical trials targeting moderately to severely active ulcerative colitis. This drug represents a beacon of hope for many patients navigating the challenges associated with such diseases.

Company Contacts and Further Information

For those interested in learning more about Abivax's journey and future opportunities, detailed insights can be found through their official website. Inquiries can also be directed to the company’s investor relations contact, Patrick Malloy, who is available to answer any questions via email at patrick.malloy@abivax.com or by phone at +1 847 987 4878.

Frequently Asked Questions

What are the CAC Mid 60 and SBF 120 indices?

These are key indices on the Euronext Paris exchange that represent mid-sized companies and a broader selection of 120 significant securities, respectively.

When does Abivax’s inclusion in the indices take effect?

The inclusion will be effective following the market's close on an upcoming Friday.

What is Abivax's primary focus as a biotechnology company?

Abivax is focused on developing therapeutics that capitalize on the body's natural mechanisms to manage inflammatory responses in chronic diseases.

What is obefazimod (ABX464) and its current status?

Obefazimod is Abivax's lead drug candidate, currently undergoing Phase 3 clinical trials for the treatment of ulcerative colitis.

How can investors learn more about Abivax?

Investors can visit Abivax's official website or contact their investor relations representative for more information.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.